244 related articles for article (PubMed ID: 33238762)
1. The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma.
Arulananda S; Lee EF; Fairlie WD; John T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):413-424. PubMed ID: 33238762
[No Abstract] [Full Text] [Related]
2. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
3. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
4. In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
Muscella A; Vetrugno C; Cossa LG; Antonaci G; De Nuccio F; De Pascali SA; Fanizzi FP; Marsigliante S
PLoS One; 2016; 11(11):e0165154. PubMed ID: 27806086
[TBL] [Abstract][Full Text] [Related]
5. The essential role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma.
Stewart JH; Tran TL; Levi N; Tsai WS; Schrump DS; Nguyen DM
J Surg Res; 2007 Jul; 141(1):120-31. PubMed ID: 17574045
[TBL] [Abstract][Full Text] [Related]
6. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
Surman DR; Xu Y; Lee MJ; Trepel J; Brown K; Ramineni M; Splawn TG; Diggs LP; Hodges HC; Davis JL; Lee HS; Burt BM; Ripley RT
Mol Cancer Ther; 2021 Aug; 20(8):1469-1480. PubMed ID: 34088830
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
9. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
[TBL] [Abstract][Full Text] [Related]
11. Gli as a novel therapeutic target in malignant pleural mesothelioma.
Li H; Lui N; Cheng T; Tseng HH; Yue D; Giroux-Leprieur E; Do HT; Sheng Q; Jin JQ; Luh TW; Jablons DM; He B
PLoS One; 2013; 8(3):e57346. PubMed ID: 23483902
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies.
Thellung S; Favoni RE; Würth R; Nizzari M; Pattarozzi A; Daga A; Florio T; Barbieri F
Curr Drug Targets; 2016; 17(7):824-49. PubMed ID: 26240051
[TBL] [Abstract][Full Text] [Related]
13. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
14. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
[TBL] [Abstract][Full Text] [Related]
15. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
Hartman ML; Czyz M
Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
[TBL] [Abstract][Full Text] [Related]
16. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
[No Abstract] [Full Text] [Related]
18. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
Opitz I; Sigrist B; Hillinger S; Lardinois D; Stahel R; Weder W; Hopkins-Donaldson S
Lung Cancer; 2007 Jun; 56(3):327-36. PubMed ID: 17383050
[TBL] [Abstract][Full Text] [Related]
19. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
20. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]